Table 2.
Symptoms and sequelae in RMD patients discharged after COVID-19
| Symptoms and sequelae | n (%) | Duration, median (IQR), days |
|---|---|---|
| Self-reported symptoms (n = 105) | 72 (68.57) | |
| Dyspnoea | 38 (36.2) | 68.5 (23–97.5) |
| Fatigue | 27 (25.71) | 38.5 (14–83) |
| Chest pain | 18 (17.14) | 30 (14–150) |
| Cough | 14 (13.33) | 27 (18–99) |
| Diarrhoea/vomiting | 14 (13.33) | 31 (15–55) |
| Fever | 11 (10.48) | 29 (22–48) |
| Anosmia/dysgeusia | 9 (8.57) | 92 (25–134) |
| Anxiety/depression | 8 (7.62) | 56.5 (22.5–73) |
| Dermatological manifestations | 7 (6.67) | 37 (27–68) |
| Joint pain | 6 (5.71) | 55 (20–68) |
| Visual/auditory alterations | 5 (4.76) | 53 (18–112) |
| Headache | 5 (4.76) | 28 (12.5–85.5) |
| Physical deconditioning | 4 (3.81) | 111 (45.5–138.5) |
| Hair loss | 2 (1.90) | 83.5 (83–84) |
| Cognitive dysfunction | 1 (0.95) | 20 |
| Sequelae (n = 105) | 31 (29.5) | |
| Death | 2 (1.90) | 13.2 (8–19) |
| Analytical abnormalities (n = 89) | 16 (17.97) | 45.5 (21–81) |
| Lung damage | 12 (10.47) | 44 (24–77.5) |
| Need for oxygen | 6 (5.7) | 20.5 (7–47) |
| Thrombotic event | 1 (0.95) | 42 |
| Optic neuritis | 1 (0.95) | 27 |
| Rehabilitation needed (physical/respiratory) | 5 (4.76) | 54 (43–88) |
The median duration of symptoms was the lag time from discharge until the last date the event was reported. The median duration of sequelae was the lag time from discharge until the sequela was reported.
IQR: interquartile range.